EMILIJA ROSENTHAL: Open Payments
NPI 1710485479 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$633 in 26 payments from 9 companies in 2025. Trend: 2023 $840 · 2024 $620 · 2025 $633
Food & beverage: $633
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 8 | $184 |
| ViiV Healthcare Company | 5 | $138 |
| Merck Sharp & Dohme LLC | 3 | $93 |
| EMD Serono, Inc. | 3 | $92 |
| Novo Nordisk Inc | 3 | $48 |
| Theratechnologies Inc. | 1 | $23 |
| Hologic Sales and Service, LLC | 1 | $20 |
| TerSera Therapeutics LLC | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: PIFELTRO, RUKOBIA, CABENUVA, Ozempic, EGRIFTA, APTIMA, Quzyttir, APRETUDE.
Industry payments across TX — which companies pay providers there.
